BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 11113845)

  • 1. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid.
    Boyce TG; Mellen BG; Mitchel EF; Wright PF; Griffin MR
    J Pediatr; 2000 Dec; 137(6):865-70. PubMed ID: 11113845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children.
    Madhi SA; Kuwanda L; Cutland C; Klugman KP
    J Clin Virol; 2006 Jul; 36(3):215-21. PubMed ID: 16678480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. School age outcome of hospitalisation with respiratory syncytial virus infection of prematurely born infants.
    Greenough A; Alexander J; Boit P; Boorman J; Burgess S; Burke A; Chetcuti PA; Cliff I; Lenney W; Lytle T; Morgan C; Raiman C; Shaw NJ; Sylvester KP; Turner J
    Thorax; 2009 Jun; 64(6):490-5. PubMed ID: 19213770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent wheezing in the third year of life among children born at 32 weeks' gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life.
    Escobar GJ; Ragins A; Li SX; Prager L; Masaquel AS; Kipnis P
    Arch Pediatr Adolesc Med; 2010 Oct; 164(10):915-22. PubMed ID: 20921348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
    Simoes EA; Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T; Rozé JC; Fauroux B;
    Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Perinatal history and hospitalization for bronchiolitis. A comparison with the impact-RSV Study Group].
    Bonillo Perales A ; DíezDelgado Rubio J ; Ortega Montes A ; Infante Márquez P ; Jiménez Liria M ; Batlles Garrido J ; López Muñoz J
    An Esp Pediatr; 2000 Dec; 53(6):527-32. PubMed ID: 11148149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
    Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
    Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.
    Stewart DL; Romero JR; Buysman EK; Fernandes AW; Mahadevia PJ
    Curr Med Res Opin; 2009 Nov; 25(11):2795-804. PubMed ID: 19788406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
    J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.
    Committee on Infectious Diseases
    Pediatrics; 2009 Dec; 124(6):1694-701. PubMed ID: 19736258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospitalization for respiratory syncytial virus infection in young children: development of a clinical prediction rule.
    Rietveld E; Vergouwe Y; Steyerberg EW; Huysman MW; de Groot R; Moll HA;
    Pediatr Infect Dis J; 2006 Mar; 25(3):201-7. PubMed ID: 16511380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR; Simoes EA; Levin MJ; Hall CB; Long CE; Rodriguez WJ; Arrobio J; Meissner HC; Fulton DR; Welliver RC
    N Engl J Med; 1993 Nov; 329(21):1524-30. PubMed ID: 8413475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Respiratory syncytial virus prophylaxis among preterm infants--four seasons' experience].
    Klimek M; Kwinta P; Kruczek P; Pietrzyk JJ
    Przegl Lek; 2009; 66(1-2):34-8. PubMed ID: 19485253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.